

Ref: MHL/Sec&Legal/2019/74

Date: February 06, 2020

To,

Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai – 400051

Scrip Code: 542650

Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Press Release for Q3FY20 Results

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that, the Company proposes to make a press release on the following topic:

'Metropolis Healthcare Limited- Q3FY20 results'

A copy of the press release to be distributed to the media is enclosed herewith.

Please take the above intimation on records.

Kindly take the same on the records.

Yours faithfully

For Metropolis Healthcare Limited



Varsha Hardasani
Compliance Officer
Membership No.: 50448
Address: Metropolis Healthcare Ltd.,
250 D, Udyog Bhavan, Hind Cycle Lane,
Worli, Mumbai- 400030



INNER HEALTH REVEALED

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030

CIN: U73100MH2000PLC192798. Tel: +91-22-3399 3939 / 6650 5555.

Email: support@metropolisindia.com | Website: www.metropolisindia.com

Central Laboratory: 4th Floor, Commercial Building-IA, Kohinoor Mall,
Vidyavihar (W), Mumbai - 400 070.

METROPOLIS
The Pathology Specialist

Metropolis Healthcare announces Q3 results

- Industry leading performance; records revenue growth of **17%** to INR **223 crore**
- Reported EBIDTA is 63cr against 51cr in Q3FY19; growth of **22.8%**
- PAT is 42 Cr as against 31.3 Cr in Q3FY19 resulting a **growth of 34.1%**
- Interim Dividend announced at Rs. 8 per equity share

Thursday, February 6, 2019 Mumbai: Metropolis Healthcare Ltd (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its un-audited consolidated financial results today for the quarter ended December 31, 2019.

Revenue	Patient Visits	No of Tests
Rs. 223 cr +17.0% YoY for Q3FY20 Rs. 190 cr in Q3FY19	2.42 Mn +14.0% YoY for Q3FY20 2.12Mn in Q3FY19	4.78 Mn +17.5% YoY for Q3FY20 4.07Mn in Q3FY19

Key Highlights Q3FY20

- Our network as of Q3FY20 consists of **125 laboratories** and **2,781 patient service centers**
- Revenue per patient in Q3FY20 is **Rs. 923** as compared to Rs. 898 in Q3FY19, an increase of 2.7% YoY
- A total of 19 new tests (7 in chemistry, 11 in molecular pathology and 1 in infectious molecular) have been validated and added to the test menu in Q3FY20 thus expanding capabilities to conduct more specialized test
- Our upcoming segment **wellness** has shown strong growth at **60%** on YoY basis. This segment now contributes to **7.9% of overall revenues** in Q3FY20
- Metropolis **TruHealth** app has been launched for the benefit of patients. This app will enable patients to view **SMARTH HEALTH** reports that give them key insights based on their previous ‘testing’ history
- Metropolis and its key management team won a total of seven awards including industry awards for Patient Experience, Best IT practices, Best Network Optimization, Excellence in Logistics and Marketing Campaigns

“We continue to post market leading performance. We are witnessing good revenue diversification amongst the focus, seeding and other cities. Growth in other cities is a good profit engine for us. We continue to deliver superior patient experience by introducing new patient centric, technology-enabled initiatives. Our B2C revenue contribution continues to grow; further reinforcing the brand value and brand recall amongst doctors and patients. With our young network, growing market share in focused cities, test menu capabilities and strong brand proposition, we are confident of continuing our growth record and become the most preferable choice for patients.”

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd

MEDIA RELEASE

GLOBAL ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

AWARDS AND ACCOLADES

Our Company was awarded **Iconic Pathology Lab** Award by Mid-Day Health & Wellness Awards in September 2018

Metropolis received the **'Best Diagnostic Laboratory'** in India award at the Women's Health Conference 2019 supported by the Ministry of AYUSH & Ministry of Health & Family Welfare.

Our Company was awarded special jury mention for **"Service Excellence (Diagnostic Centre)"** by FICCI at the Healthcare Excellence Awards 2018

Our Company was awarded for **"Excellence in Customer Service & Delivery"** by Biotrains, 2018

Metropolis Healthcare won the **Best Temperature Controlled Project of the year** at the Cold Chain Summit Awards held in Mumbai, 2018

Metropolis Healthcare honored for **Excellence in Customer Service & Delivery** at the Home Healthcare Summit & Awards 2018

Awards won in Q3 – October – December 2020

Metropolis won the award for Best IT Practices at the Data Center Summit, 2019 – October 2019

Metropolis won the **'Best Logistics Network Optimization'** & **'Best use of Technology in Logistics'** awards announced at the 5th Asian Supply Chain Thought Leadership Summit & Awards in Mumbai. November 2019

Our Chairman, **Dr. Sushil Shah**, won the **'Lifetime Achievement Award'** at the South Asia Pacific Healthcare Summit & Business Awards, 2019 for his immense contribution to the diagnostic industry. December 2019

Our MD, **Ms. Ameera Shah** won the **'Best Woman Entrepreneur of the Year'** in Healthcare Sector award at the ASSOCHAM Women Leadership & Empowerment Summit & Awards for her outstanding leadership and achievements in the diagnostic industry. December 2019

Metropolis won the **Patient Experience team of the Year Award** at PEXA Awards 2019 in Delhi December 2019

Metropolis also bagged **'Excellence in Logistics'** award at the **CII SCALE Awards 2019** - Supply Chain & Logistics Excellence Awards organized by **Confederation of Indian Industries** December 2019

Metropolis won a special mention as the **Best Performance-Driven Digital Campaign Award** at the InkSpell Drivers of Digital Awards 2019. December 2019

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 19 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade; which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company	Investor Relations Advisors:
 <p>Metropolis Healthcare Limited CIN - U73100MH2000PLC192798</p>	 <p>Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285</p>
<p>Ms. Nadhiya Mali – Corporate Communications corpcomm@metropolisindia.com investor.relations@metropolisindia.com www.metropolisindia.com</p>	<p>Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net / sagar.shroff@sgapl.net +91-77383 77756 / +91-9820519303 www.sgapl.net</p>